News from DURECT Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 14, 2017, 16:02 ET DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2016 and provided a corporate...


Feb 24, 2017, 16:55 ET DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a...


Jan 30, 2017, 08:00 ET DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program's lead...


Oct 31, 2016, 16:03 ET DURECT Corporation Announces Third Quarter 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016. Total revenues were $3.7 million and net loss...


Oct 31, 2016, 16:02 ET DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort...


Oct 21, 2016, 16:30 ET DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a...


Sep 26, 2016, 07:05 ET DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII

 DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter...


Sep 06, 2016, 08:00 ET DURECT to Present at the Rodman & Renshaw Global Investment Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global...


Jul 25, 2016, 17:29 ET DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference Call

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a...


Jul 01, 2016, 09:05 ET DURECT Provides REMOXY® Update

DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug...


Jun 28, 2016, 16:30 ET DURECT to Present at the Cantor Fitzgerald Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald...


May 31, 2016, 08:30 ET DURECT to Present at the Jefferies Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the Jefferies...


May 19, 2016, 09:05 ET DURECT Announces FDA Advisory Committee Meeting for REMOXY®

DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of...


May 11, 2016, 09:05 ET DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting

DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual...


May 05, 2016, 16:05 ET DURECT Corporation Announces First Quarter 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016.  Total revenues were $3.6 million and net...


Apr 29, 2016, 12:15 ET DURECT Announces Closing of Public Offering of Common Stock

DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered...


Apr 28, 2016, 16:30 ET DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the...


Apr 26, 2016, 09:00 ET DURECT Announces Pricing of Public Offering of Common Stock

DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered...


Apr 25, 2016, 16:01 ET DURECT Announces Proposed Public Offering of Common Stock

 DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an...


Feb 29, 2016, 16:05 ET DURECT Corporation Announces Fourth Quarter 2015 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2015. Total revenues were $5.2 million...


Feb 18, 2016, 16:30 ET DURECT Corporation Invites You to Join its Fourth Quarter 2015 Earnings Conference Call

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2015 financial results press release, you are invited to listen to the...


Jan 28, 2016, 17:00 ET DURECT to Present at the BIO CEO & Investor Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor...


Jan 11, 2016, 08:00 ET DURECT Announces Initiation of DUR-928 Dosing in Patients

DURECT Corporation (Nasdaq: DRRX) today announced it has initiated a single-ascending-dose Phase 1b clinical trial with DUR-928 in patients with...


Jan 06, 2016, 08:00 ET DURECT Announces Positive Phase 1 Data for DUR-928

 DURECT Corporation (Nasdaq: DRRX) today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of...


Nov 30, 2015, 16:15 ET DURECT to Present at the Oppenheimer Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Oppenheimer Healthcare...